Υπέρταση και Νεφροί: Οι βλάβες, η διάγνωση, η θεραπεία

Transcript

1 Υπέρταση και Νεφροί: Οι βλάβες, η διάγνωση, η θεραπεία Δημήτριος Β. Βλαχάκος Αναπληρωτής Καθηγητής Νεφρολογίας B Προπαιδευτική Παθολογική Κλινική Νεφρολογική Μονάδα Πανεπιστημιακό Γ.Ν. «ΑΤΤΙΚΟΝ»

2 Υπέρταση και Νεφροί: Οι βλάβες, η διάγνωση, η θεραπεία

3 Αγγεία και Υπέρταση

4 Characterized histologically by arteriolar hyalinosis caused by insudation of plasma proteins and medial thickening caused by both hypertrophy and hyperplasia of vascular smooth muscle cells (periodic acid-schiff stain, 200). Characteristics of benign nephrosclerosis Renal dysfunction probably due to compensatory glomerular hyperfiltration Increase glomerular pressure is associated with proteinuria Hyperfiltration of certain glomeruli tends to induce sclerosis Renal impairment progresses slowly; after 10 yr, only 1 to 2% of pts develop renal dysfunction.

5 Renal manifestation of malignant hypertension Renal failure within days-weeks; Treatment: typically IV vasodilators e.g. nitroprusside sodium or nitroglycerin Three renal histological changes associated with malignant hypertension 1) Arteriolar fibrinoid necrosis 2) Hyperplastic arteriosclerosis {arteriolar "onion-skinning"} 3) Glomerulitis in the hypercellular glomerulus

6

7 Υπέρταση και Νεφροί: Οι βλάβες, η διάγνωση, η θεραπεία

8

9 Υπολογισμός νεφρικής καθάρσεως (ml/min) (140-ηλικία σε έτη) Χ (Βάρος σε Kg) (72 ή 85 ) Χ (Κρεα,mg%)

10 60 ml/min Βλάβη Νόσος Stage I Stage II Stage III Stage IV Stage V Kidney damage with normal or GFR Kidney damage with mild GFR Moderate GFR Severe GFR Kidney failure Glomerular filtration rate (ml/min/1.73m 2 ) National Kidney Foundation. Am J Kidney Dis 2002; 39(2 Suppl 1):S1 S266

11 Ο βαθμός της νεφρικής βλάβης αποτελεί ανεξάρτητο παράγοντα κινδύνου για θάνατο από καρδιαγγειακή νόσο, JACC 2003

12 Μικροαγγειοπάθεια

13 Parameter Normal Macroalbuminuria Microalbuminuria Urine AER (µg/min) < >200 Urine AER (mg/24h) < >300 Urine albumin/ Cr # ratio (mg/gm) < >300 AER=Albumin excretion rate CR # =creatinine

14

15 ΥΠΕΡΤΑΣΗ ΠΡΩΤΕΪΝΟΥΡΙΑ ΧΝΝ

16

17 ESRD Due to Any Cause In 332,544 Men Screened for MRFIT Adjusted Relative Risk Adjusted Relative Risk 25,0 20,0 15,0 10,0 5,0 0,0 * p< ,0 1,2 1.9* Optimal Normal High Normal Men with optimal blood pressure was the reference category. 3.1* 6* 11.2* 22.1* Stage 1 Stage 2 Stage 3 Stage 4 Blood Pressure Category Hypertension Klag MJ, et al. NEJM 1996;334:13-18.

18 ΥΠΕΡΤΑΣΗ ΠΡΩΤΕΪΝΟΥΡΙΑ ΧΝΝ

19

20 ΥΠΕΡΤΑΣΗ ΠΡΩΤΕΪΝΟΥΡΙΑ ΧΝΝ

21

22 Υπέρταση και Νεφροί: Οι βλάβες, η διάγνωση, η θεραπεία

23

24 GFR ml/min ESH, 2003

25 GFR < 60 ml/min ESH, 2003

26 Lower BP Results in Slower Rates of Decline in GFR GFR (ml/min/year) MAP (mmhg) /85 140/90 r = 0.69; P < 0.05 Untreated HTN Bakris GL, et al. Am J Kidney Dis. 2000;36(3):

27 Aggressive Blood Pressure Control Modification of Diet in Renal Disease Study Mean fall in GFR (ml/min/year) Low BP (125/75 mm Hg) Usual BP (130/80 mm Hg) Mean GFR = 39 ml/min 0 < 1 g/day g/day >= 3 g/day Klahr S et al: N Engl J Med 330: , 1994

28 Treatment of Patients with Kidney Disease < 1 gm Proteinuria >1gm Proteinuria BP treatment goal # drugs required <130/80 ~2-3 <125/75 ~3-4

29 Intraglomerular pressure DHP CCB nondhp CCB ACEi, ARB s Renin Antagonists

30 Μεταβολή σπειραματικής διήθησης με την αναστολή του άξονα Ρενίνης-Αγγειοτασίνης ΚΑΘΑΡΣΗ ΧΡΟΝΟΣ

31 ACE-I is More Renoprotective than Conventional Therapy in Type 1 Diabetes (Total N = 409) % with Doubling of Baseline Creatinine Captopril Conventional therapy 100 Baseline creatinine > 1.5 mg/dl Decrease in Mean Blood Pressure (mm Hg) % Reduction in Proteinuria P < NS - 60 Lewis et al. N Engl J Med. 1993;329: American College of Physicians. All Rights Reserved.

32 Irbesartan in Diabetic Nephropathy Trial: Time to Doubling of Serum Creatinine, ESRD, or Death Subjects (%) ,715 Type 2 Diabetics with Nephropathy Irbesartan BP 140/77 Amlodipine BP 141/77 Placebo BP 144/80 RRR 23% P=.006 P=NS RRR 20% P=.02 Percent Reduction Change in Proteinuria Irbesartan Amlodipine Placebo Lewis EJ, et al. N Engl J Med. 2001;345: Follow-up (mo) American College of Physicians. All Rights Reserved. 60

33 The REIN Study

34 ΣΥΝΔΙΑΣΜΕΝΗ ΘΕΡΑΠΕΙΑ ΜΕ ΑΜΕΑ & ΑRBs ΚΑΙ ΥΦΕΣΗ ΛΕΥΚΩΜΑΤΟΥΡΙΑΣ (MacKinnon M et al, Am J Kidney DIs 2007;48;8-20)

35 COOPERATE, Lancet 2003

36 COOPERATE, Lancet 2003 Endpoint: Doubling of serum creatinine or ESRD

37 Outcome ONTARGET: Incidence of primary and R, n (%) secondary renal outcomes T, n (%) R + T, n (%) T vs R HR p R + T vs R HR p All dialysis, doubling of creatinine, death 1150 (13.4) 1147 (13.4) 1233 (14.5) All dialysis and doubling of creatinine 174 (2.03) 189 (2.21) 212 (2.49) R=ramipril T=telmisartan Mann JFE et al. Lancet 2008; 372:

38 ΤΗΙΝΚ KIDNEY!! -LOGOS NEPHRON NEPHROLOGY ΔΙΑΓΝΩΣΗ ΠΡΟΓΝΩΣΗ ΘΕΡΑΠΕΙΑ ΕΥΧΑΡΙΣΤΩ ΠΟΛΥ!